Showing 6,421 - 6,440 results of 18,005 for search 'significantly ((((less decrease) OR (teer decrease))) OR (a decrease))', query time: 0.57s Refine Results
  1. 6421

    Changes in the neutrophil count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  2. 6422

    Changes in the platelet count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  3. 6423

    Changes in the white blood cell count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  4. 6424

    Changes in the hemoglobin. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  5. 6425

    WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  6. 6426

    General clinical data of 88 patients with NPC. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  7. 6427

    CONSORT participant flow diagram. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  8. 6428

    S4 File - by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  9. 6429

    Data Sheet 6_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  10. 6430

    Data Sheet 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  11. 6431

    Data Sheet 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  12. 6432

    Data Sheet 5_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  13. 6433
  14. 6434
  15. 6435

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  16. 6436

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  17. 6437

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  18. 6438

    Data Sheet 1_Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized control... by Sumaiah J. Alarfaj (12889115)

    Published 2025
    “…</p>Results<p>Compared to the placebo group (n = 24), the atorvastatin group (n = 23) exhibited a significant decrease in the level of IL-6 (p = 0.001), S1P (p = 0.0001), TNF-α (p = 0.003), NO (p = 0.0001), CRP (p = 0.015), ESR (p = 0.012), PMS (p = 0.013), and fecal calprotectin (p = 0.0003), and improved SF-36 (p = 0.006). …”
  19. 6439
  20. 6440